Olson Matthew T, Nuransoy Ayşe, Ali Syed Z
Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Acta Cytol. 2013;57(2):177-83. doi: 10.1159/000345696. Epub 2013 Feb 28.
Malignant serous cavity effusion caused by primary thyroid cancer is extremely rare in routine clinical practice. Therefore, it is often not included in the differential diagnostic workup of patients presenting with positive effusion cytology.
The clinical features were reviewed for 6 patients seen at our institution over the last 26 years for malignant effusion resulting from metastatic thyroid cancer. The cytomorphology from 4 of these cases was also reviewed.
All of the patients found in this study presented with malignant pleural effusion - other serous cavity effusions resulting from metastatic thyroid carcinoma were not seen. These comprised 0.25% of all patients with a known history of thyroid carcinoma and 0.67% of all malignant pleural effusions. One patient had a history of bone metastases, but all the others had no pathological evidence of distant metastatic disease prior to the pleural effusion.
Malignant pleural effusion rarely results from a thyroid carcinoma after some latency. The diagnosis requires immunohistochemical staining as well as the pertinent clinical context.
在常规临床实践中,原发性甲状腺癌引起的恶性浆膜腔积液极为罕见。因此,在积液细胞学检查呈阳性的患者的鉴别诊断检查中,通常不包括这种情况。
回顾了过去26年在我们机构就诊的6例因转移性甲状腺癌导致恶性积液患者的临床特征。还回顾了其中4例的细胞形态学。
本研究中发现的所有患者均表现为恶性胸腔积液,未见到转移性甲状腺癌导致的其他浆膜腔积液。这些患者占所有已知甲状腺癌病史患者的0.25%,占所有恶性胸腔积液的0.67%。1例患者有骨转移病史,但其他所有患者在出现胸腔积液之前均无远处转移疾病的病理证据。
甲状腺癌在经过一段时间的潜伏期后很少导致恶性胸腔积液。诊断需要免疫组化染色以及相关的临床背景。